Clinical background of AML patients with and without NPM1 mut
| . | All (N = 146) . | NPM1+ (n = 83) . | . | NPM1− (n = 63) . | . | ||
|---|---|---|---|---|---|---|---|
| . | AR <0.5 (n = 31) . | AR ≥0.5 (n = 52) . | P . | < 0.5 (n = 27) . | ≥ 0.5 (n = 36) . | P . | |
| Age (y), median (range) | 56 (18-90) | 58 (26-80) | 56 (18-90) | .873 | 52 (21-86) | 55 (20-90) | .673 |
| Sex | |||||||
| Male | 66 | 13 | 15 | .240 | 17 | 21 | .797 |
| Female | 77 | 17 | 36 | .239 | 8 | 15 | .430 |
| Unknown | 4 | 1 | 1 | 1.000 | 2 | 0 | .180 |
| ECOG-PS, 0/1/2/3/4 | 41/45/6/3/3 | 12/9/1/0/0 | 11/19/3/2/2 | 9/7/0/3/0 | 9/10/2/0/1 | ||
| WBC count, median (range), ×109/L | 60.4 (1.0-677.0) | 49.9 (1.0-470.5) | 85.6 (2.1-677.0) | .519 | 36.2 (1.1-620.0) | 48.9 (1.3-450.1) | 0.570 |
| Hb, median (range), g/dL | 8.5 (3.5-15.1) | 8.9 (3.3-14.3) | 8.5 (4.4-14.9) | .756 | 8.0 (4.1-15.0) | 8.7 (4.1-15.1) | .926 |
| Plt count, median (range), ×109/L | 50.0 (5.0-630.0) | 49.0 (11.0-160.0) | 45.0 (5.0-339.0) | .708 | 82.0 (6.0-630.0) | 50.0 (6.0-540.0) | .602 |
| LDH, median (range), IU/L | 718 (151-5930) | 588 (204-3788) | 695 (156-4144) | .093 | 718 (151-5930) | 819 (157-3915) | 0.891 |
| FAB | |||||||
| M0 | 6 | 0 | 2 | .526 | 1 | 3 | 0.629 |
| M1 | 51 | 13 | 22 | 1.000 | 4 | 12 | 0.144 |
| M2 | 36 | 7 | 8 | .556 | 11 | 10 | .296 |
| M4 | 29 | 5 | 8 | 1.000 | 8 | 8 | .566 |
| M5 | 17 | 4 | 10 | .554 | 0 | 3 | .253 |
| Not determined | 7 | 2 | 2 | .627 | 3 | 0 | .073 |
| Chromosomal aberrations | |||||||
| t(8,21) | 4 | 0 | 0 | 1.000 | 2 | 2 | 1.000 |
| inv(16) | 1 | 0 | 0 | 1.000 | 1 | 0 | .429 |
| Normal | 105 | 23 | 46 | .130 | 16 | 20 | .802 |
| Trisomy 8 | 3 | 0 | 0 | 1.000 | 0 | 3 | .253 |
| 11q23 | 0 | 0 | 0 | 1.000 | 0 | 0 | 1.000 |
| Complex | 4 | 0 | 1 | 1.000 | 1 | 2 | 1.000 |
| Unknown | 8 | 2 | 3 | 1.000 | 2 | 1 | .572 |
| Gene mutation | |||||||
| FLT3-TKD | 0 | 0 | 0 | 1.000 | 0 | 0 | 1.000 |
| CEBPA(sm) | 8 | 2 | 1 | .553 | 3 | 2 | 0.643 |
| CEBPA(dm) | 3 | 0 | 0 | 1.000 | 3 | 0 | 0.073 |
| Induction therapy | |||||||
| (IDA/DNR/ACR) + Ara-C | 108 | 24 | 39 | 1.000 | 17 | 28 | .262 |
| AVVV, BHAC-DM, CAG | 24 | 5 | 6 | .739 | 6 | 7 | 1.000 |
| Others | 14 | 2 | 7 | .473 | 4 | 1 | .155 |
| Stem cell transplantation | |||||||
| All | 65 | 12 | 22 | .821 | 14 | 17 | .801 |
| In CR1 | 31 | 8 | 6 | .130 | 8 | 9 | .777 |
| . | All (N = 146) . | NPM1+ (n = 83) . | . | NPM1− (n = 63) . | . | ||
|---|---|---|---|---|---|---|---|
| . | AR <0.5 (n = 31) . | AR ≥0.5 (n = 52) . | P . | < 0.5 (n = 27) . | ≥ 0.5 (n = 36) . | P . | |
| Age (y), median (range) | 56 (18-90) | 58 (26-80) | 56 (18-90) | .873 | 52 (21-86) | 55 (20-90) | .673 |
| Sex | |||||||
| Male | 66 | 13 | 15 | .240 | 17 | 21 | .797 |
| Female | 77 | 17 | 36 | .239 | 8 | 15 | .430 |
| Unknown | 4 | 1 | 1 | 1.000 | 2 | 0 | .180 |
| ECOG-PS, 0/1/2/3/4 | 41/45/6/3/3 | 12/9/1/0/0 | 11/19/3/2/2 | 9/7/0/3/0 | 9/10/2/0/1 | ||
| WBC count, median (range), ×109/L | 60.4 (1.0-677.0) | 49.9 (1.0-470.5) | 85.6 (2.1-677.0) | .519 | 36.2 (1.1-620.0) | 48.9 (1.3-450.1) | 0.570 |
| Hb, median (range), g/dL | 8.5 (3.5-15.1) | 8.9 (3.3-14.3) | 8.5 (4.4-14.9) | .756 | 8.0 (4.1-15.0) | 8.7 (4.1-15.1) | .926 |
| Plt count, median (range), ×109/L | 50.0 (5.0-630.0) | 49.0 (11.0-160.0) | 45.0 (5.0-339.0) | .708 | 82.0 (6.0-630.0) | 50.0 (6.0-540.0) | .602 |
| LDH, median (range), IU/L | 718 (151-5930) | 588 (204-3788) | 695 (156-4144) | .093 | 718 (151-5930) | 819 (157-3915) | 0.891 |
| FAB | |||||||
| M0 | 6 | 0 | 2 | .526 | 1 | 3 | 0.629 |
| M1 | 51 | 13 | 22 | 1.000 | 4 | 12 | 0.144 |
| M2 | 36 | 7 | 8 | .556 | 11 | 10 | .296 |
| M4 | 29 | 5 | 8 | 1.000 | 8 | 8 | .566 |
| M5 | 17 | 4 | 10 | .554 | 0 | 3 | .253 |
| Not determined | 7 | 2 | 2 | .627 | 3 | 0 | .073 |
| Chromosomal aberrations | |||||||
| t(8,21) | 4 | 0 | 0 | 1.000 | 2 | 2 | 1.000 |
| inv(16) | 1 | 0 | 0 | 1.000 | 1 | 0 | .429 |
| Normal | 105 | 23 | 46 | .130 | 16 | 20 | .802 |
| Trisomy 8 | 3 | 0 | 0 | 1.000 | 0 | 3 | .253 |
| 11q23 | 0 | 0 | 0 | 1.000 | 0 | 0 | 1.000 |
| Complex | 4 | 0 | 1 | 1.000 | 1 | 2 | 1.000 |
| Unknown | 8 | 2 | 3 | 1.000 | 2 | 1 | .572 |
| Gene mutation | |||||||
| FLT3-TKD | 0 | 0 | 0 | 1.000 | 0 | 0 | 1.000 |
| CEBPA(sm) | 8 | 2 | 1 | .553 | 3 | 2 | 0.643 |
| CEBPA(dm) | 3 | 0 | 0 | 1.000 | 3 | 0 | 0.073 |
| Induction therapy | |||||||
| (IDA/DNR/ACR) + Ara-C | 108 | 24 | 39 | 1.000 | 17 | 28 | .262 |
| AVVV, BHAC-DM, CAG | 24 | 5 | 6 | .739 | 6 | 7 | 1.000 |
| Others | 14 | 2 | 7 | .473 | 4 | 1 | .155 |
| Stem cell transplantation | |||||||
| All | 65 | 12 | 22 | .821 | 14 | 17 | .801 |
| In CR1 | 31 | 8 | 6 | .130 | 8 | 9 | .777 |
Data are numbers of patients, except as noted. Some data are missing due to the unavailability of certain follow-up data in a retrospective study.
HU, hydroxyurea.